Stelo

Stelo by Dexcom is a continuous glucose monitor biosensor and the glucose-biometric entry in the cohort, recorded in the biometric form factor as a boundary include because glucose is in the biometric definition and Stelo pairs an FDA-cleared sensor with a genuine generative-AI insight layer rather than being a bare sensor readout. Made by DexCom (NASDAQ: DXCM) as a product line separate from its prescription G7 monitors, Stelo is the first-ever FDA-cleared over-the-counter, no-prescription continuous glucose biosensor, cleared via De Novo announced on March 5, 2024 and launched in the US on August 26, 2024 for adults 18 and older who are not on insulin, including people with type 2 diabetes not on insulin and non-diabetic users tracking the impact of diet and exercise, with a 15-day wear and no low-glucose alerts since it is not cleared for problematic hypoglycemia. Its AI augmentation is genuine: Dexcom launched a generative-AI platform for Stelo on Google Cloud's Vertex AI and Gemini, providing personalized Weekly Insights, AI photo meal logging, and up to three personalized daily recommendations drawn from glucose, activity, nutrition, and sleep, which is what tips it from a medical sensor to an in-definition biometric-AI device and fills the glucose cell distinct from the heart-rate and sleep watches and rings. Its FDA clearance makes it the strongest verification anchor of the Wave-2 set, while the marketing claim of being the first generative-AI platform in glucose biosensing is not load-bearing and is not asserted, and its exclusion of low-glucose alerting is recorded as an indication boundary.

Stelo is listed at $89 to $99 on the DEPLOY registry. This is an actual sale price on record.

Yes. Stelo is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.

Stelo's recorded specifications on the DEPLOY registry: Battery: 15 days; Weight: 0.005 kg. See the Specs section for the full sourced set.

Stelo is made by Dexcom, based in San Diego, California, USA, founded in 1999.

2 verified deployments of Stelo are on the DEPLOY registry, including at United Kingdom, Global.

Stelo is available for purchase - a real sale price is on record (see the pricing section for the figure and its source).

Stelo has 2 regulatory records on the DEPLOY registry: FDA 510(k) clearance (K234070), cleared; FDA 510(k) clearance (K234070), cleared. See the Regulatory filings section for each agency source.

On the DEPLOY registry, comparable biometric robots to Stelo include Blackrock Neuroport Array, BrainQ Non-Invasive BCI, Neko Body Scan, RNS System.

Stelo and Blackrock Neuroport Array (Blackrock Neurotech · 5 deployments) are both biometric robots on the DEPLOY registry. Stelo has 2 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Stelo ranks in roughly the top 10% of biometric models tracked by the registry.

Stelo is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.

Stelo has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.

Stelo is a non-prescription over-the-counter (OTC) glucose biosensor by Dexcom that tracks glucose 24/7. It is an integrated Continuous Glucose Monitor (iCGM) suitable for adults (18+ years) not on insulin. FDA-cleared under 510(k) K234070. No prescription required.